Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 355 · 1 trial · 1 indication
Adverse events (AEs) are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs), and clinical laboratory tests, as assessed by the investigator, will also be reported as TEAEs.
| Arm | Type | Description |
|---|---|---|
| Group A: AMG 355 monotherapy | EXPERIMENTAL | Specified dose on specified days |
| Group B: AMG 355 and pembrolizumab | EXPERIMENTAL | Specified dose on specified days |
| Name | Type | Description |
|---|---|---|
| AMG 355 | DRUG | Short-term intravenous (IV) infusion |
| Pembrolizumab | DRUG | Short-term IV infusion |
Key Inclusion Criteria: * Age ≥ 18 years at the time of signing informed consent. * Participants with histologically or cytologically confirmed metastatic or locally advanced solid tumors who have relapsed after and/or are refractory to or ineligible for established and available therapies with kno...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AMG 355 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being evaluated in a Phase 1 clinical trial, both alone and in combination with pembrolizumab, in participants with advanced solid tumors. The drug is not yet approved and remains in clinical development.
AMG 355 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting a Phase 1 clinical trial of AMG 355 in patients with advanced solid tumors.
AMG 355 is in Phase 1 clinical development. It is an investigational drug being studied for advanced solid tumors, and it has not been approved by regulatory authorities. The Phase 1 trial has been completed.
AMG 355 is being studied in a Phase 1 clinical trial with the identifier NCT06131398. This trial evaluates AMG 355 alone and in combination with pembrolizumab in participants with advanced solid tumors. The trial has been completed and enrolled 77 participants.
No, AMG 355 is not the same as pembrolizumab. AMG 355 is an investigational small molecule being developed by Amgen, while pembrolizumab is an approved immunotherapy. The Phase 1 trial NCT06131398 studies AMG 355 alone and in combination with pembrolizumab.